Genetic Technologies (ASX:GTG) Debt-to-Asset : 0.14 (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Debt-to-Asset?

Genetic Technologies ASX:GTG Debt-to-Asset is 0.14 as of Jun. 2024.

Genetic Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.85 Mil. Genetic Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.02 Mil. Genetic Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was A$6.19 Mil. Genetic Technologies's debt to asset for the quarter that ended in Jun. 2024 was 0.14.

Genetic Technologies  (ASX:GTG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genetic Technologies Debt-to-Asset Related Terms

Genetic Technologies Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Debt-to-Asset Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.03 0.04 0.14

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.05 0.00 0.14 0.00

ASX:GTG vs LDDD, NOTV, ATLN: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Debt-to-Asset falls into.


Genetic Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genetic Technologies's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.852 + 0.023) / 6.187
=0.14

Genetic Technologies's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.852 + 0.023) / 6.187
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.14 mean?
Genetic Technologies (ASX:GTG) has a Debt-to-Asset of 0.14 as of Jun. 2024. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Debt-to-Asset too high?
Genetic Technologies' current Debt-to-Asset is 0.14.
How does Genetic Technologies' Debt-to-Asset compare to LDDD and NOTV?
Genetic Technologies' Debt-to-Asset of 0.14 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Debt-to-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Debt-to-Asset of 0.14. The current Debt-to-Asset is 0.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Debt-to-Asset is 0.14 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.